Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for QDEL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quidel Corp ranked in the 41th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Quidel Corp, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 44.05; that's higher than 91.42% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 7.15% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 51.49% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as QDEL, try STE, MEDP, AMGN, INBP, and NVS.
Global urinalysis market is expected to reach USD 8,767.60 million by 2027 from USD 4,994.50 million in 2019 growing with the substantial CAGR of 7.3% in the forecast period of 2020 to 2027. The Urinalysis market report will help all the
Quidel had its Relative Strength (RS) Rating upgraded from 67 to 75 Tuesday — a welcome improvement for the producer of rapid diagnostic tests, but still short of the 80 or better score you look for. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary RS Rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.